Dabrafenib and trametinib–induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma Authors: Kohei Nagano, Masaki Suzuki, Saki Morikawa, Rikiya Watanabe, Takeshi Ohara, Kenta Hara Published: 2026 ABSTRACT AbstractHyperglycemia is an adverse effect of targeted cancer therapies; however, the mechanisms underlying B-Raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibitor-associated hyperglycemia remain unclear. We describe an 80-year-old man who developed severe hyperglycemia during combination therapy with dabrafenib and trametinib for BRAF V600E-positive lung adenocarcinoma. Before treatment, he was obese and had unrecognized mild diabetes. Seven months after treatment initiation, he presented with hyperglycemia accompanied by a reduced insulin secretory capacity. Serial measurements of the C-peptide index revealed that the temporary withdrawal of dabrafenib–trametinib resulted in the recovery of insulin secretion, which gradually decreased again upon reinitiation. This case underscores the clinical importance of monitoring both the glycemic status and insulin secretion in patients receiving BRAF/MEK inhibitors. Introduction Hyperglycemia is a significant adverse effect of chemotherapy and molecularly targeted therapies. Treatment-associated hyperglycemia has been linked to poorer clinical outcomes, underscoring the need for early detection and appropriate management [1, 2]. Among molecularly targeted agents used in oncology, several agents affect insulin signaling pathways, including the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway and rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, which play essential roles in metabolic regulation and cellular proliferation [3]. B-Raf proto-oncogene, serine/threonine kinase (BRAF) and MEK inhibitors suppress the RAF/MEK/ERK signaling pathway. They are widely used in the treatment of malignancies harboring the BRAF V600E mutation, including non–small cell lung cancer [4]. Combination therapy with dabrafenib and trametinib causes grade 3 or higher hyperglycemia requiring hospitalization and insulin therapy in 3.0% to 9.0% of patients [5, 6]. Therefore, the monitoring of plasma glucose levels is recommended [7]; however, the underlying mechanisms remain unclear. Moreover, few longitudinal evaluations have been conducted on the insulin secretory capacity during drug discontinuation and reinitiation in patients who develop hyperglycemia during BRAF/MEK inhibitor therapy. We report a case of hyperglycemia during combined dabrafenib and trametinib therapy for lung adenocarcinoma, in which serial C-peptide measurements before and after drug discontinuation suggested the reversible impairment of insulin secretion. Case presentation An 80-year-old man was admitted to our department for the management of hyperglycemia 209 days after the initiation of BRAF/MEK inhibitor therapy for lung adenocarcinoma. Computed tomography (CT) performed 76 days before initiating BRAF/MEK inhibitors revealed multiple nodular lesions along the right pleura and diaphragm (Fig. 1A). Biopsy confirmed BRAF V600E-positive lung adenocarcinoma. Therefore, dabrafenib (300 mg/day) and trametinib (2 mg/day) were initiated. At that time, body weight was 87.0 kg, the body mass index (BMI) was 25.7 kg/m2, and previously unrecognized diabetes was suspected based on hemoglobin A1c (HbA1c) of 6.7% (International System of Units [SI]: 50 mmol/mol) (reference range, <6.0% [SI: <42 mmol/mol]), according to the American Diabetes Association diagnostic criteria. CT performed 41 days before admission revealed no clear progression of multiple nodular lesions along the right pleura and diaphragm (Fig. 1B), with no evidence of a pancreatic lesion (Fig. 1C). CT images were obtained 76 days before initiating BRAF/MEK inhibitor therapy (A), and 41 days before admission (B: chest and C: abdomen). Axial CT scans show multiple nodular lesions along the right pleura and diaphragm (arrows, A, B), with no clear progression observed on the follow-up image (B). Abdominal CT scan shows no evidence of a pancreatic lesion (C). Diagnostic assessment On admission, BMI was 25.5 kg/m2, and a physical examination and vital signs were unremarkable, except for decreased breath sounds in the right lower field. His comorbidities included obesity, dyslipidemia, hypertension, atrial fibrillation, and chronic obstructive pulmonary disease. His current medications included dabrafenib, trametinib, rosuvastatin, ω-3 fatty acid ethyl esters, irbesartan, efonidipine hydrochloride, edoxaban, lansoprazole, and tiotropium bromide hydrate, with no prior antidiabetic medications. He had smoked 15-20 cigarettes per day for 60 years, from 20 to 80 years of age. Laboratory tests revealed a random plasma glucose level of 442 mg/dL (SI: 24.5 mmol/L), serum C-peptide level 1.70 ng/mL (SI: 0.56 nmol/L) (reference range, 0.78-5.19 ng/mL [SI: 0.26-1.72 nmol/L]), HbA1c 11.0% (SI: 97 mmol/mol), immunoreactive insulin level 6.4 μIU/mL (SI: 44.4 pmol/L) (reference range, 5-10 μIU/mL [SI: 34.7-69.5 pmol/L]), and anti-glutamic acid decarboxylase antibody level <5.0 U/mL (SI: <5.0 kU/L) (reference range, <5.0 U/mL [SI: <5.0 kU/L]). The C-peptide index (CPI), calculated as C-peptide (ng/mL) × 100/plasma glucose (mg/dL), was 0.38. A glucagon challenge test on day 7 showed a prechallenge plasma glucose level of 137 mg/dL (SI: 7.6 mmol/L) and C-peptide level of 1.04 ng/mL (SI: 0.34 nmol/L), which increased to 2.21 ng/mL (SI: 0.73 nmol/L) at 6 minutes (ΔC-peptide: 1.17 ng/mL [SI: 0.39 nmol/L]) (Table 1). A prior episode of pneumonia, treated with ceftriaxone without corticosteroids 4 months before admission, was unlikely to have contributed to subsequent glycemic deterioration. Table 1Laboratory findings at presentation and during the clinical courseHematologic characteristics (2 days prior to admissiona)Reference rangeLab valuesWBC3300-8600/µL (3.30-8.60 × 109/L)6980/µL (6.98 × 109/L)RBC4.56-5.55 × 106/µL (4.56-5.55 × 1012/L) 4.55 × 106/µL (4.55 × 1012/L)Hemoglobin13.7-16.8 g/dL (137-168 g/L)14.1 g/dL (141 g/L)Platelet158-348 × 103/µL (158-348 × 109/L)230 × 103/µL (230 × 109/L) Biochemical characteristics (2 days prior to admission a ) Sodium135.0-146.0 mmol/L (135.0-146.0 mmol/L) 134.2 mmol/L (134.2 mmol/L) Potassium3.50-5.00 mmol/L (3.50-5.00 mmol/L) 5.09 mmol/L (5.09 mmol/L) Chloride96.0-108.0 mmol/L (96.0-108.0 mmol/L)97.3 mmol/L (97.3 mmol/L)Urea nitrogen8.0-20.0 mg/dL (2.9-7.1 mmol/L)14.6 mg/dL (5.2 mmol/L)Creatinine0.60-1.10 mg/dL (53-97 µmol/L)0.96 mg/dL (85 µmol/L)eGFR>60 mL/min/1.73 m2 (>60 mL/min/1.73 m2) 58.0 mL/min/1.73 m2 (58.0 mL/min/1.73 m2)Albumin3.9-4.9 g/dL (39-49 g/L) 3.8 g/dL (38 g/L) AST13-33 U/L (13-33 U/L)28 U/L (28 U/L)ALT8-42 U/L (8-42 U/L)34 U/L (34 U/L)γ-GTP10-47 U/L (10-47 U/L) 48 U/L (48 U/L) LDH124-222 U/L (124-222 U/L) 234 U/L (234 U/L) Amylase37-124 U/L (37-124 U/L)40 U/L (40 U/L)C-reactive protein0.00-0.30 mg/dL (0.0-3.0 mg/L)0.21 mg/dL (2.1 mg/L)Plasma glucose70-109 mg/dL (3.9-6.0 mmol/L) 442 mg/dL (24.5 mmol/L) Hemoglobin A1c<5.9% (<41 mmol/mol) 11.0% (97 mmol/mol) C-peptide0.78-5.19 ng/mL (0.26-1.72 nmol/L)1.70 ng/mL (0.56 nmol/L)IRI5-10 µIU/mL (34.7-69.5 pmol/L)6.4 µIU/mL (44.4 pmol/L)GAD antibodies<5.0 U/mL (<5.0 kU/L)<5.0 U/mL (<5.0 kU/L) Venous blood gas analysis (2 days prior to admission a ) pH7.31-7.417.38CO239.8-50.3 mmHg (5.3-6.7 kPa)45.6 mmHg (6.1 kPa)HCO3−22.0-29.0 mEq/L (22.0-29.0 mmol/L)27.2 mEq/L (27.2 mmol/L)Base excess−2.0 to +2.0 mEq/L (−2.0 to +2.0 mmol/L)1.5 mEq/L (1.5 mmol/L)Anion gap8.0-16.0 mEq/L (8.0-16.0 mmol/L)7.8 mEq/L (7.8 mmol/L) Urinalysis findings (1 day prior to admission a ) ProteinNegativeNegativeGlucoseNegative 4+ Ketone bodiesNegativeNegative Endocrinological characteristics (2 days prior to admission a ) TSH0.61-4.23 µIU/mL (0.61-4.23 mIU/L)0.99 µIU/mL (0.99 mIU/L)FT40.70-1.48 ng/dL (9.0-19.1 pmol/L)0.92 ng/dL (11.8 pmol/L)FT31.88-3.18 pg/mL (2.9-4.9 pmol/L)2.41 pg/mL (3.7 pmol/L) Endocrinological characteristics (Hospital day 1) ACTH7.0-63.0 pg/mL (1.5-13.0 pmol/L)15.6 pg/mL (3.4 pmol/L)Cortisol4.0-18.3 µg/dL (110-505 nmol/L)11.3 µg/dL (312 nmol/L) Glucagon challenge test (Hospital day 7) FPG (0 minutes)70-109 mg/dL (3.9-6.0 mmol/L) 137 mg/dL (7.6 mmol/L) FPG (6 minutes)NA148 mg/dL (8.2 mmol/L)C-peptide (0 minutes)0.78-5.19 ng/mL (0.26-1.72 nmol/L)1.04 ng/mL (0.34 nmol/L)C-peptide (6 minutes)NA2.21 ng/mL (0.73 nmol/L) Urinalysis findings (Hospital day 2) Urinary C-peptide23.7-206.9 µg/day (7.8-68.5 nmol/day)49.5 µg/day (16.4 nmol/day)SI units are shown in parentheses.Abnormal values are shown in bold font.Hospital day 0 is the date of admission to our department.Abbreviations: ACTH, adrenocorticotropic hormone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; FT3, free triiodothyronine; FT4, free thyroxine; GAD antibodies, glutamic acid decarboxylase antibodies; γ-GTP, γ-glutamyl transpeptidase; IRI, immunoreactive insulin; LDH, lactate dehydrogenase; NA, not available; RBC, red blood cell count; TSH, thyroid-stimulating hormone; WBC, white blood cell count. a Blood samples on 2 days prior to admission were collected at 18:00 under nonfasting (random) conditions. Laboratory findings at presentation and during the clinical course SI units are shown in parentheses. Abnormal values are shown in bold font. Hospital day 0 is the date of admission to our department. Abbreviations: ACTH, adrenocorticotropic hormone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; FT3, free triiodothyronine; FT4, free thyroxine; GAD antibodies, glutamic acid decarboxylase antibodies; γ-GTP, γ-glutamyl transpeptidase; IRI, immunoreactive insulin; LDH, lactate dehydrogenase; NA, not available; RBC, red blood cell count; TSH, thyroid-stimulating hormone; WBC, white blood cell count. a Blood samples on 2 days prior to admission were collected at 18:00 under nonfasting (random) conditions. Treatment Dabrafenib and trametinib were suspended for 28 days starting on the day of admission. Beginning the day after admission, multiple daily insulin injections of glargine and aspart were initiated, with doses being titrated based on plasma glucose levels. Metformin (500 mg/day) and empagliflozin (10 mg/day) were initiated on days 5 and 7, respectively. By hospital day 15, the treatment regimen consisted of insulin glargine (8 units/day), metformin hydrochloride (500 mg/day), and empagliflozin (10 mg/day), achieving a fasting plasma glucose level of 114 mg/dL (SI: 6.3 mmol/L) at discharge. Outcome and follow-up Twenty-eight days after the discontinuation of dabrafenib and trametinib, laboratory testing showed an increase in fasting CPI to 3.42 (plasma glucose, 116 mg/dL (SI: 6.4 mmol/L); C-peptide 3.97 ng/mL [SI: 1.31 nmol/L]). This value was significantly higher than fasting CPI of 0.46 measured on day 3 after admission. Following the resumption of BRAF/MEK inhibitor therapy, fasting CPI gradually decreased with fluctuations, reaching 1.72 (plasma glucose 105 mg/dL [SI: 5.8 mmol/L]; C-peptide 1.81 ng/mL [SI: 0.60 nmol/L]; HbA1c 6.8% [SI: 51 mmol/mol]) 250 days after reinitiation of BRAF/MEK inhibitors (Fig. 2). CT performed 412 days after the initiation of BRAF/MEK inhibitor therapy revealed a sustained reduction in the sizes of multiple nodular lesions along the right pleura and diaphragm. Clinical course and changes in glycemic parameters during BRAF and MEK inhibitor therapy. The graph illustrates the relationship between the administration of dabrafenib and trametinib and the patient's glycemic control. Dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, were initiated on day 0. Treatment was temporarily held twice: first due to pneumonia (days 53-69) and subsequently due to the onset of severe hyperglycemia (day 209; plasma glucose 442 mg/dL), which led to admission. During the first treatment interruption due to pneumonia, CPI data were unavailable. The pneumonia was successfully treated with ceftriaxone at 2 g/day for 7 days, without the use of corticosteroids. During the 28-day discontinuation following the onset of hyperglycemia, the fasting CPI recovered to a peak of 3.42. After resuming BRAF/MEK inhibitor therapy on day 237, the CPI showed a gradual, fluctuating decline, reaching 1.72 by day 487. The red line indicates plasma glucose levels, and the blue line indicates CPI. Red numbers represent plasma glucose levels, with values in parentheses indicating HbA1c levels at the corresponding time points. Blue numbers represent CPI. Asterisks (*) indicate blood samples collected under nonfasting (random) conditions. All other plasma glucose and CPI values were obtained under fasting conditions. Abbreviations: CPI, C-peptide index; CPR, C-peptide immunoreactivity; HbA1c, hemoglobin A1c. Discussion Two important findings emerged from this case. Based on serial changes in CPI, pancreatic β-cell dysfunction appears to be the primary mechanism underlying BRAF/MEK inhibitor-associated hyperglycemia. Furthermore, recovery of the insulin secretory capacity upon the discontinuation of BRAF/MEK inhibitors and the subsequent decline after reinitiation demonstrate that the suppression of insulin secretion is reversible. Although the glucagon stimulation test on hospital day 7 did not indicate absolute insulin deficiency, this result needs to be interpreted cautiously because it was obtained after initiating insulin therapy and partially ameliorating severe hyperglycemia. It may represent an impaired β-cell secretory reserve still under the suppressive effects of BRAF/MEK inhibitors, which is further supported by the restoration of fasting CPI to 3.42 after 28 days of drug discontinuation. Although testing at admission may have provided baseline β-cell function, performing a glucagon challenge under severe hyperglycemia was clinically difficult and potentially unsafe. The RAF/MEK/ERK signaling pathway has been reported to play a dual role in glucose metabolism, and its effects vary with the organ and activation mode (physiological vs chronic excessive). The RAF/MEK/ERK pathway contributes to the development of insulin resistance in the liver and adipose tissue. Although insulin has been shown to induce the activation of MEK, ERK1/2, and S6 peptide kinase in intact rat livers [8], increased hepatic ERK activity in leptin-deficient ob/ob mice or diet-induced obese mice leads to insulin resistance [9]. In the latter context, this phenomenon may be explained by ERK1/2 overactivation, which interferes with insulin signaling by phosphorylating serine residues on insulin receptor substrate 1 (IRS1). Serine phosphorylation negatively regulates the interaction between IRS1 and the insulin receptor or the p85 subunit of PI3K [10, 11]. The ERK pathway was also shown to be activated in the adipose tissue of obese mouse models, and the administration of MEK inhibitors improved insulin sensitivity [12]. In addition, the RAF/MEK/ERK pathway plays a vital role in both the quantitative maintenance and functional regulation of pancreatic β-cells and in insulin gene transcription. Mice with the β cell-specific deletion of MEK1/2 exhibited a reduced β-cell mass upon high-fat diet feeding, impaired insulin secretion during glucose tolerance tests, and consequent glucose intolerance [13]. Since these mice also had a reduced β-cell mass even on a standard diet, the MEK/ERK pathway appears to be essential not only for compensatory β-cell hyperplasia, but also for maintaining the β-cell mass. Furthermore, the two-photon excitation imaging of islets isolated from these mice revealed impaired insulin granule exocytosis in response to Ca2+ influx. In addition, ERK1/2 was found to regulate the glucose-stimulated transcription of rat insulin promoters in primary islets, at least in part by phosphorylating key transcription factors, including pancreatic and duodenal homeobox 1 and neurogenic differentiation 1 [14]. In humans, a reduction in MEK/ERK pathway activity has been suggested to contribute to impaired pancreatic β-cell function. In nonobese patients with type 2 diabetes, the percentage of the β-cell area was reduced, and ERK1/2 phosphorylation in pancreatic β-cells was lower than that in healthy individuals, suggesting the contribution of decreased MEK/ERK pathway activity to β-cell dysfunction [13]. Single nucleotide polymorphisms (SNPs) near ras guanyl nucleotide-releasing protein 1, which is involved in RAS activation, and dual specificity phosphatase 9 (DUSP9), an ERK-selective cytoplasmic phosphatase, have been associated with type 2 diabetes [15]. Furthermore, SNPs near BRAF have been implicated in the development of type 2 diabetes and with changes in BRAF expression in pancreatic islets [16, 17]. Collectively, these findings—except for those associated with DUSP9—support the hypothesis that hyperglycemia induced by BRAF/MEK inhibitors may be associated with impaired pancreatic β-cell function. In contrast, DUSP9, a potential negative regulator of ERK signaling, may contribute to insulin resistance in the liver or adipose tissue by overactivating the ERK pathway. These findings suggest that the administration of BRAF/MEK inhibitors leads to an improvement in or the deterioration of glucose tolerance. This raises the question of why glucose tolerance worsened after the initiation of therapy in the present case. In obese mouse models, the administration of MEK inhibitors (PD0325901 and PD184352) was found to improve glucose tolerance within 5 to 14 days after treatment initiation [12, 18]. In contrast, in our patient, the deterioration of glucose tolerance, associated with reduced insulin secretion, occurred only after long-term treatment, approximately 7 months after the initiation of BRAF/MEK inhibitor therapy. This temporal discrepancy suggests that the timing of the effects of BRAF/MEK inhibitors on the liver and adipose tissue differs from that on pancreatic β-cells. Suda et al also reported a case of lung cancer complicated by hyperglycemia, in which worsening glucose tolerance became evident six months after the initiation of BRAF/MEK inhibitor therapy [19]. The CPI improvement observed 28 days after drug discontinuation may be attributed to both the alleviation of glucotoxicity and restoration of drug-induced toxicity. Previous studies demonstrated that β-cell function recovered from glucotoxicity within 14 days of intensive insulin therapy, with a mean time to euglycemia of 5.6 days [20]. Therefore, recovery in our patient may reflect, at least partly, the reversal of direct drug-induced toxicity. Although β-cell restoration after BRAF/MEK inhibitor discontinuation has yet to be reported in detail, we speculate from our clinical observations that the underlying mechanism involves the recovery of insulin expression and granule exocytosis rather than a change in the β-cell mass. There are several limitations that need to be addressed. The potential parallel contribution of the changes observed in insulin sensitivity is of considerable interest; however, data to assess insulin sensitivity, such as fasting insulin levels, were not available before developing hyperglycemia. Therefore, an early assessment of peripheral insulin sensitivity using methods such as euglycemic clamp studies is warranted because both insulin sensitivity and secretion need to be considered in relation to treatment duration. Furthermore, the optimal frequency and clinical utility of routine C-peptide monitoring remain unclear because β-cell decline may occur unpredictably. In addition, the patient's 60-year smoking history may have contributed to impaired β-cell function, which cannot be entirely distinguished from drug-induced effects. Learning points Combination therapy with BRAF and MEK inhibitors may induce late-onset hyperglycemia, even after several months of treatment. Combination therapy with BRAF and MEK inhibitors may induce late-onset hyperglycemia, even after several months of treatment. Hyperglycemia in this case is most likely attributable to impaired β-cell function; however, the findings should not be over-generalized from a single case. Hyperglycemia in this case is most likely attributable to impaired β-cell function; however, the findings should not be over-generalized from a single case. Regular monitoring of plasma glucose levels and the insulin secretory capacity needs to be considered in patients receiving BRAF/MEK inhibitor therapy. Regular monitoring of plasma glucose levels and the insulin secretory capacity needs to be considered in patients receiving BRAF/MEK inhibitor therapy.